Загрузка...
A patient with ALK‐positive lung adenocarcinoma who survived alectinib‐refractory postoperative recurrence for 4 years by switching to ceritinib
Echinoderm microtubule‐associated protein‐like 4‐anaplastic lymphoma kinase (EML4‐ALK) rearrangements are found in ~ 5% of patients with non‐small cell lung cancer (NSCLC). Several tyrosine kinase inhibitors (TKIs) have been developed for treatment of so‐called ALK‐positive NSCLC. In cases of tumor...
Сохранить в:
| Опубликовано в: : | Thorac Cancer |
|---|---|
| Главные авторы: | , , , , , , , , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
John Wiley & Sons Australia, Ltd
2021
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8327688/ https://ncbi.nlm.nih.gov/pubmed/34159737 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.14058 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|